Artemis Medicare Services Limited has informed the Exchange regarding a press release dated May 12, 2025, titled "Artemis consolidated gross revenue up 7% in Q4; EBITDA up 21%; Net Profit up 60%".
ARTEMISMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Artemis Medicare Services reported Q4 FY25 consolidated gross revenue of Rs 2,521 million, up 7% year-on-year, with EBITDA rising 21% to Rs 482 million and net profit jumping 60% to Rs 229 million. For the full fiscal year FY25, gross revenue grew 6.5% to Rs 9,819 million, EBITDA reached Rs 1,848 million (margin of 19.7%), and net profit rose to Rs 822 million from Rs 491 million. The Board has recommended a final dividend of 45% per share (face value Re 1) for FY25, subject to shareholder approval. Key operational highlights include ARPOB improving to Rs 82,800, overseas patient revenue up 26.5% to Rs 725 million (32% of net revenue), and bed utilisation at 60.8%. The company also raised Rs 330 crore from the International Finance Corporation (IFC) to fund expansion across Delhi NCR and select Tier 2 cities, and approved an agreement for a 300+ bed super-speciality hospital in Raipur, marking its entry into Central India.
Strong double-digit growth in profits and EBITDA expansion signals healthy operating leverage and margin improvement, likely to be viewed positively by investors. The final dividend, IFC fundraising, and Raipur expansion signal management's confidence and a clear growth runway, which could support the stock in the near term.